Related Experiment Video

Updated: May 23, 2026

Elevated Plus Maze for Mice
09:09

Elevated Plus Maze for Mice

Published on: December 22, 2008

Genetic suppression of agrin reduces mania-like behavior in Na+ , K+ -ATPase α3 mutant mice

G S Kirshenbaum1, S J Clapcote, J Petersen

  • 1Samuel Lunenfeld Research Institute, Mount Sinai Hospital Institute of Medical Science, University of Toronto, Toronto, ON, Canada. greershelby@gmail.com

Insights

Reducing agrin, a synaptic proteoglycan, alleviates mania-like behaviors and normalizes circadian rhythms in Myshkin mice by restoring Na(+) ,K(+) -ATPase activity. This highlights agrin as a therapeutic target for neurological disorders.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Myshkin mice, with a mutation in the neuron-specific Na(+) ,K(+) -ATPase α3 isoform, exhibit mania-like behaviors and altered circadian rhythms.
  • Agrin, a synaptic proteoglycan, is hypothesized to inhibit Na(+) ,K(+) -ATPase α3 activity.

Purpose of the Study:

  • To investigate if reducing agrin expression genetically can rescue mania-like behaviors in Myshkin mice.
  • To determine the role of agrin in regulating Na(+) ,K(+) -ATPase activity and circadian rhythms.

Main Methods:

  • Genetic knockout of agrin in Myshkin mice.
  • Behavioral assessments including hyperambulation, holeboard exploration, anxiety-like behavior, and prepulse inhibition.
  • Measurement of brain Na(+) ,K(+) -ATPase activity.

Main Results:

  • Agrin suppression ameliorated hyperambulation, holeboard exploration, and risk-taking behavior, while improving prepulse inhibition and normalizing circadian period.
  • In Myshkin mice, agrin suppression increased brain Na(+) ,K(+) -ATPase activity by 11 ± 4%.
  • No significant change in Na(+) ,K(+) -ATPase activity was observed in wild-type mice with agrin suppression.

Conclusions:

  • Agrin plays a crucial role in regulating mania-like behavior and circadian rhythms.
  • Targeting agrin may offer a therapeutic strategy for mania and related neurological conditions characterized by reduced Na(+) ,K(+) -ATPase activity and neuronal hyperexcitability.